PDMR Shareholding

RNS Number : 6867E

C4X Discovery Holdings PLC

22 October 2018

 

C4X Discovery Holdings plc

("C4XD" or the "Company")

PDMR Shareholdings

22 October 2018 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, announces that Dr Craig Fox, Chief Scientific Officer, has today purchased 5,900 ordinary shares of 1 pence each in the Company ("Ordinary Shares"), at a price of 86.7 pence per Ordinary Share (the "Dealing"). Following the Dealing, Dr Craig Fox holds 7,183 Ordinary Shares.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and/or persons closely associated with them:

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Dr Craig Fox
2	Reason for the notification
a)	Position/status	Chief Scientific Officer, Director
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	C4X Discovery Holdings plc
b)	LEI	213800UHNL82E323O870
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	1p ordinary shares ISIN GB00BQQ2RV18
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) per Ordinary Share Volume(s) 86.7p 5,900
d)	Aggregated information	Price Volume(s) £5,115.30 5,900
e)	Date of the transaction	19 October 2018
f)	Place of the transaction	London Stock Exchange - AIM

Name of authorised official of issuer responsible for making notification: Brad Hoy, Chief Financial Officer of the Company.

--ENDS-

For further information, please contact:

C4X Discovery Holdings plc

Clive Dix, Chief Executive Officer                                                                                                          07801 865 803

Panmure Gordon (UK) Limited (NOMAD)                                                                                          020 7886 2500

Freddy Crossley, Emma Earl (Corporate Finance)                                                                                             

James Stearns (Corporate Broking)                                                                                                                        

Consilium Strategic Communications                                                                                              020 3709 5700

Mary-Jane Elliott, Matthew Neal, Chris Gardner                                                                                                        

About C4X Discovery

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.

C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3®) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. This provides new and unprecedented insight into the behaviour of drug molecules, enabling the production of potent selective compounds faster and more cost effectively than the industry standard.

C4X Discovery is advancing its in-house pipeline that is primarily focused on the high value therapeutic areas of inflammation, neurodegeneration and cancer (including immuno-oncology) with a number of new drug candidates identified and further progress made towards pre-clinical licensing discussions. In selecting and executing new drug discovery programmes, C4X Discovery focuses on high-value disease areas that are the subject of significant licensing activity and will continue to also maximise value from opportunistic areas such as addiction and diabetes. The Company recently signed a licensing agreement with Indivior for a pre-clinical addiction programme worth up to $294 million.

The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD to reach multiple value inflexion points since IPO. For additional information please go to: www.c4xdiscovery.com

--ENDS----

 

END

 

 

DSHMBBBTMBMTTPP